You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美康生物(300439.SZ):2019年由盈轉虧 淨虧損5.60億元
格隆匯 04-28 08:05

格隆匯4月28日丨美康生物(300439.SZ)披露2019年年度報告,報告期內,公司實現營業收入31.33億元,同比下降0.05%;歸屬於上市公司股東的淨利潤為虧損5.60億元,而上年同期為盈利2.41億元;經營活動現金淨流入6.01億元,同比增長43.54%;基本每股虧損1.63元。

報告期內,公司堅持自主創新,繼續加大對產品研發的投入,研發投入1.28億元,比上年同期增加了16.98%,保持研發技術的創新性與先進性,不斷提升技術創新和新產品開發實力。報告期內公司在研發方面取得階段性成果如下:

公司高速生化分析儀MS-2080、中速生化分析儀MS-680取得註冊證獲准生產上市,標誌着公司生化分析儀從低端到中高端已全面佈局完成,能全面滿足各級醫療機構的需求;公司獲得包括甲功、性激素、糖代謝、心肌等共計24項化學發光產品註冊證,進一步完善和豐富了公司產品線,為公司未來發展提供新的增長點。

公司將從美國引進的先進VAP血脂亞組分檢測技術成功在國內進行研發註冊,取得VAP血脂分型儀器和試劑2項註冊證,進一步豐富和完善公司產品線,VAP血脂亞組分檢測技術能全面及時發現血脂的代謝異常及紊亂,更加精準地發現心血管疾病的風險因素,克服了當前基礎血脂檢測的不足,為臨牀提供精準全面的心血管疾病診斷治療依據,較傳統血脂檢測更早提出健康保健意見,對公司進入心血管疾病檢測領域具有積極意義。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account